2023-04
喜讯 | 博生吉医药TAA06注射液顺利完成I期临床试验的首例患者回输
中国苏州,2023年4月17日——博生吉医药科技,一家以突破性细胞新药研发为主要业务的国家高新技术企业,今日公告,公司自主研...
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co. Ltd is a biotech company focusing on developing leading-edge cellular therapeutics. The company is committed to developing CAR-related therapeutic and analytical antibodies, novel CAR- products, and allogeneic cellular therapies. The company has developed a comprehensive pipeline of products and a world-leading allogeneic off-the-shelf UCAR-Vδ1 T-cell R&D platform.
PersonGen.Anke Cellular Therapeutics Co., Ltd.
PersonGen-Anke Cellular Therapeutics Co., Ltd. is a subsidiary company and the manufacturing base of PersonGen BioTherapeutics. The company is equipped with the global-leading fully-automated, closed manufacturing system for cellular therapeutics. It also has the most advanced facilities for the manufacturing of clinical-grade DNA plasmids and lentiviruses. The company has developed fully validated manufacturing processes of CAR-T, allogeneic γδT and UCAR-γδT products.
Read More
PersonGen BioTherapeutics is one of the first company in China focusing on the development of CAR-T and other cellular immunotherapies.
We are driven by our values “Care for People, Cure Every Patient”, and is committed to being the world leader on developing allogeneic cellular therapies against tumors and autoimmunity diseases.
中国苏州,2023年4月17日——博生吉医药科技,一家以突破性细胞新药研发为主要业务的国家高新技术企业,今日公告,公司自主研...
2024年9月6日,博生吉与苏州大学唐仲英医学研究院、北京大学肿瘤医院合作研究的新一代通用现货型B7-H3-CAR-γδT细胞治疗多种实体肿...
自2017年首款CAR-T获批以来,全球癌症免疫细胞疗法研发热度一直居高不下,且发展出了包括NK/CAR-NK、TIL、TCR-T、CAR-...
5月31日下午,合肥市2023年度合肥工匠、职工技术创新成果暨职工职业技能等级提升激励发布仪式在合肥市总工会举行。市人大常委会副主任、市总工...
博生吉PA3-17注射液是全球首款获得新药临床研究批准(IND)的自体CD7-CAR-T细胞产品,分别于2021年11月和2022年12月被...
Conceptual Pilot Study, Patient Recruitment
Read More